Search
Minnesota Paid Clinical Trials
A listing of 2064 clinical trials in Minnesota actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
697 - 708 of 2064
Minnesota is currently home to 2064 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Minneapolis, Rochester, Saint Paul and Duluth. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Studying an Investigational Virus Vaccine
Recruiting
The main objectives of this study are to assess the safety and effectiveness of an investigational vaccine aimed at preventing norovirus, commonly known as the stomach flu. Participants will be randomly assigned to receive either the investigational vaccine or a placebo. Should you express interest, you will be contacted directly by the research site, which will provide further details and answer any questions you may have about study requirements, risks/benefits, and any compensation.
Conditions:
Healthy
Interested in vaccine studies
All Conditions
Preventative Trials
Featured Trial
Type 2 Diabetes Clinical Trial
Recruiting
Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.
Conditions:
Type 2 Diabetes
Diabetes Mellitus Type 2 in Obese
Diabetes Type Two
Type 2 Diabetes Mellitus
Diabete Type 2
Featured Trial
Evaluating an Investigational Treatment for Hidradenitis Suppurativa
Recruiting
The main objectives of this Phase 2 study are to evaluate the safety and effectiveness of an investigational medication in adults with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition. Participants will be randomly assigned to receive the investigational treatment or a placebo. Should you express interest, the research site will contact you directly to provide further details and address any questions you may have about study requirements, risks/benefits, and compensation.
Conditions:
All Conditions
Hidradenitis suppurativa (Skin disorder)
Dermatology
Featured Trial
High Triglyceride Clinical Research Study
Recruiting
Living with high triglycerides? See if our clinical study is right for you.
Don’t let financial stress hold you back. All clinical study-related assessments, care, and the investigational study drug are available at no cost. You could also be eligible for compensation for travel.
Don’t let financial stress hold you back. All clinical study-related assessments, care, and the investigational study drug are available at no cost. You could also be eligible for compensation for travel.
Conditions:
High Triglycerides
High Triglyceride Level
Hypertriglyceridemia
Elevated Triglycerides
Triglycerides High
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
Recruiting
The main purpose of this study is to evaluate the safety and efficacy of novel study interventions and combinations in participants with Colorectal Cancer (CRC).
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
03/19/2025
Locations: Research Site, Rochester, Minnesota
Conditions: Metastatic Colorectal Cancer
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
Recruiting
This is a parallel-group, Phase 2, randomized, double-blind, placebo-controlled, 2-arm study for the treatment of asthma.
The purpose of this study is to assess the efficacy, safety, and tolerability of add-on therapy with SC lunsekimig compared with placebo in male and female participants (aged 18 to 80 years, inclusive) with asthma, who are not currently eligible for biologic treatments.
Study details include:
* The study duration will be approximately 64 weeks for participants not transiti... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
03/19/2025
Locations: Javara - Mankato Clinic- Site Number : 8400001, Mankato, Minnesota
Conditions: Asthma
Investigations of Reproductive Cancers in Women
Recruiting
The goal of this study is to create a non-invasive diagnostic test to rule out gynecological cancer in females aged 45 and older with abnormal uterine or postmenopausal bleeding.
Gender:
FEMALE
Ages:
Between 45 years and 100 years
Trial Updated:
03/19/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Uterine Cancer
Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial
Recruiting
The Gram-negative bloodstream infection Oral Antibiotic Therapy trial (The GOAT Trial) is a multi-center, randomized clinical trial that hypothesizes that early transition to oral antibiotic therapy for the treatment of Gram-Negative BloodStream Infection (GN-BSI) is as effective but safer than remaining on intravenous (IV) antibiotic therapy for the duration of treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Gram-negative Bacteremia
Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)
Recruiting
To Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects with Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA).
The primary objective is to evaluate the effect of seladelpar treatment at Week 52 compared to placebo based on normalization of alkaline phosphatase (ALP) defined by a composite endpoint of ALP ≤ 1.0× upper limit of normal (ULN) and ≥ 15% decrease from baseline in PBC participants with... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/19/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Primary Biliary Cholangitis
R-5280 in Newly Diagnosed Patients with Type 1 Diabetes
Recruiting
Evaluating the adverse events and tolerance of R-5280 in Mitigating Type 1 Diabetes in Newly Diagnosed Patients
Gender:
ALL
Ages:
Between 11 years and 17 years
Trial Updated:
03/19/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Type 1 Diabetes, Type 1 Diabetes (Juvenile Onset), Diabetes Mellitus, Type 1
INTERogating Cancer for Etiology, Prevention and Therapy Navigation
Recruiting
This study is being done to identify markers and causes of cancer by analyzing patient's DNA (i.e., genetic material), RNA, plasma, tissues, or other samples that could be informative for patients with cancer. Cancer genetic testing is a series of tests that finds specific changes in cancer cells and normal cells in the body. Researchers may request to access these data as they explore how to better prevent, screen, or treat cancer. This study is also being done to create a biobank (library) of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Cancer, Cancer Gene Mutation, PAN Gene Mutation, Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm
R-3750 in Patients with Mild to Moderate Ulcerative Colitis
Recruiting
The goal of this study is to determine the safety and tolerability of orally taken probiotic (R-3750) in patients with mild to moderate ulcerative colitis.
Patients will take an oral dosage of probiotic (R-3750) and provide patient-reported and physician scored measures of their colitis. Blood and fecal evaluations of inflammation and assessment of probiotic (R-3750) on fecal levels will also be measured.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/19/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Ulcerative Colitis Chronic Mild, Ulcerative Colitis Chronic Moderate, Ulcerative Colitis Chronic, Ulcerative Colitis
Physio-Anatomy Clinical Data Collection Study
Recruiting
This is an on-label clinical study design intended for the collection of three different types of interventional procedural data using FDA-cleared cardiac catheterization technologies and drugs, each used according to its product labeling and standard practice of medicine.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2025
Locations: Minneapolis VA Medical Center, Minneapolis, Minnesota
Conditions: Coronary Stenosis
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
Recruiting
The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin, glofitamab, or mosunetuzumab, and to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) for the combinations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Recruiting
This phase II trial studies the effects of venetoclax and rituximab in comparison to ibrutinib and rituximab in treating patients with previously untreated Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Lymphoplasmacytic Lymphoma, Waldenstrom Macroglobulinemia
Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.
Recruiting
Multi-center, global, prospective, non-randomized, interventional, pre-market trial. All subjects enrolled with receive the study device.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2025
Locations: Abbott Northwestern Hospital, Minneapolis, Minnesota
Conditions: Mitral Valve Regurgitation